Lead Product(s) : Emilimogene Sigulactibac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ILP100-Topical (emilimogene sigulactibac) is a first-in-class immunotherapy designed to treat surgical wounds in patients with prediabetes, diabetes and obesity.
Product Name : ILP100
Product Type : Microorganism
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Emilimogene Sigulactibac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyxone Will Leverage IND and Use FDA Pre-Review for Covid-19 Phase 2 Trial
Details : Rabeximod is is an orally administered immunomodulator being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections.
Product Name : Rob 803
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyxone Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod
Details : The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery.
Product Name : Rob 803
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VP01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results show restoration of lung function in COVID-19 on top of corticosteroids and remdesivir with the company's oral drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.
Product Name : VP01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2021
Lead Product(s) : VP01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Results Show that C21 Can Become an Important Complement to COVID-19 Vaccines
Details : The data show restoration of lung function in COVID-19 with the company’s oral lead candidate drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyxone Files Patent Application to Extend Exclusivity of Rabeximod
Details : An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.
Product Name : Rob 803
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2020
Lead Product(s) : Rabeximod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ATTRACT study investigated the efficacy of oral C21 compared with placebo in COVID-19 patients with signs of an acute respiratory infection but not requiring mechanical ventilation. Oral C21 treatment demonstrates significant clinical improvement on ...
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore Pharma Doses First COVID-19 Patient in the ATTRACT Study in India
Details : The primary objective with the study, named ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial), is to investigate efficacy of VP01 (C21) on COVID-19 infection not requiring mechanical ventilation.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VP01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore Pharma BAGS MHRA Nod for Covd-19 Trial in Record Time
Details : Vicore Pharma got approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to start a Phase II clinical trial assessing a potential COVID-19 therapy in record time.
Product Name : VP01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : VP01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable